WallStreetZenWallStreetZen

NYSEMKT: CHRO
Chromocell Therapeutics Corp Earnings & Revenue

OverviewEarnings
DividendOwnership

CHRO past revenue growth

How has CHRO's revenue growth performed historically?
Company
N/A
Industry
144.63%
Market
17.55%
CHRO's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CHRO's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance

CHRO earnings and revenue history

Current Revenue
$0.0
Current Earnings
-$7.4M
Current Profit Margin
0%

CHRO Return on Equity

Insufficient data to display

Be the first to know when CHRO announces earnings.

CHRO Return on Assets

Current Company
-11,824.5%
Current Industry
2.9%
CHRO is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

CHRO Return on Capital Employed

Current Company
106.48%
Current Industry
19.5%
CHRO has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

CHRO vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
CHRO$0.00-$6.86M-$7.38M-100.00%N/A
AEZS$4.50M-$16.38M-$16.55M-30.06%N/A
MTEM$57.31M$1.16M-$8.12M+33.96%-92.71%
ERNA$68.00k-$19.93M-$21.68M-68.89%N/A
CMMB$0.00-$24.15M-$24.22MN/AN/A
View Top Biotech Stocks

Chromocell Therapeutics Earnings & Revenue FAQ

What were CHRO's earnings last quarter?

Chromocell Therapeutics (NYSEMKT: CHRO) reported Q4 2023 earnings per share (EPS) of -$5.42, up 8.18% year over year. Total Chromocell Therapeutics earnings for the quarter were -$4.04 million. In the same quarter last year, Chromocell Therapeutics's earnings per share (EPS) was -$5.01.

If you're new to stock investing, here's how to buy Chromocell Therapeutics stock.

What was CHRO's earnings growth in the past year?

As of Q2 2024, Chromocell Therapeutics's earnings has grown year over year. Chromocell Therapeutics's earnings in the past year totalled -$7.38 million.

What was CHRO's revenue last quarter?

Chromocell Therapeutics (NYSEMKT: CHRO) reported Q4 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Chromocell Therapeutics's revenue was $0.00.

What was CHRO's revenue growth in the past year?

As of Q2 2024, Chromocell Therapeutics's revenue has grown null year over year. Chromocell Therapeutics's revenue in the past year totalled $0.00.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.